Incidence of pancreas graft thrombosis using low-molecular-weight heparin

Clin Transplant. 2009 Jun-Jul;23(3):407-14. doi: 10.1111/j.1399-0012.2008.00911.x.

Abstract

Introduction: Simultaneous pancreas-kidney transplantation is the current treatment of choice for patients with type I diabetes and end stage renal disease. Vascular graft thrombosis (VGT) after pancreas transplantation is the main cause of early graft loss.

Methods: A total of 188 consecutive pancreas transplantations were performed between January 2000 and December 2006. A retrospective study was carried out in order to compare incidence of VGT and relaparotomy-for-bleeding rate of once daily fixed dose low-molecular-weight-heparin (LMWH) to dose-adjusted intravenous unfractionated heparin (UFH).

Results: Fifty-eight patients receiving LMWH and 129 receiving UFH were identified. There were 7% (4/58) VGTs in the LMWH and 17% (22/129) in the UFH group (p = 0.047). The frequency of major bleeding requiring relaparatomy was not significantly different in the groups related to LMWH and UFH, respectively (6.9% vs. 7.8%). One yr patient and pancreas graft survival was 98.9/89.6% in the LMWH and 97.8/74.4% in the UFH group. Donor and recipient characteristics were similar.

Conclusion: In our experience once daily fixed dose LMWH might not be inferior to dose-adjusted intravenous heparin in preventing pancreas graft thrombosis.

MeSH terms

  • Adult
  • Anticoagulants / administration & dosage*
  • Anticoagulants / adverse effects
  • Female
  • Heparin / adverse effects
  • Heparin, Low-Molecular-Weight / administration & dosage*
  • Humans
  • Injections, Subcutaneous
  • Kaplan-Meier Estimate
  • Kidney Transplantation*
  • Male
  • Middle Aged
  • Pancreas Transplantation / adverse effects*
  • Postoperative Care
  • Retrospective Studies
  • Thrombosis / prevention & control*

Substances

  • Anticoagulants
  • Heparin, Low-Molecular-Weight
  • Heparin